Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP NASDAQ:DYAI NASDAQ:OTLK NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$9.85+1.1%$8.84$4.64▼$58.90$114.83M3.0897,333 shs153,927 shsDYAIDyadic International$0.98+2.9%$0.95$0.71▼$2.20$33.34M0.94121,169 shs111,358 shsOTLKOncobiologics$0.89+2.3%$1.99$0.79▼$8.32$38.65M0.486.87 million shs5.26 million shsTARAProtara Therapeutics$3.23+1.9%$3.12$1.60▼$10.48$122.31M1.52157,961 shs434,818 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals+1.13%-5.92%+5.46%+11.93%-82.31%DYAIDyadic International+2.89%+5.18%-3.05%+0.23%-25.25%OTLKOncobiologics+2.29%-62.61%-55.72%-52.41%-86.80%TARAProtara Therapeutics+1.89%0.00%+2.22%+3.53%+68.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals3.8706 of 5 stars3.62.00.04.72.01.70.0DYAIDyadic International3.398 of 5 stars3.55.00.00.02.53.30.0OTLKOncobiologics2.4574 of 5 stars4.22.00.00.02.00.00.6TARAProtara Therapeutics2.7073 of 5 stars3.63.00.00.02.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 3.10Buy$49.00397.46% UpsideDYAIDyadic International 3.00Buy$6.00512.75% UpsideOTLKOncobiologics 2.33Hold$9.60978.65% UpsideTARAProtara Therapeutics 3.17Buy$19.60506.81% UpsideCurrent Analyst Ratings BreakdownLatest DYAI, TARA, CRBP, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/28/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.008/28/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral8/27/2025OTLKOncobiologicsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.008/6/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $53.007/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$28.007/12/2025CRBPCorbus PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/6/2025OTLKOncobiologicsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $21.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$9.06 per shareN/ADYAIDyadic International$3.49M10.15N/AN/A($0.01) per share-97.92OTLKOncobiologics$1.51M26.26N/AN/A($0.84) per share-1.06TARAProtara TherapeuticsN/AN/AN/AN/A$3.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)DYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)OTLKOncobiologics-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/ATARAProtara Therapeutics-$44.60M-$1.62N/AN/AN/AN/A-36.87%-33.85%11/11/2025 (Estimated)Latest DYAI, TARA, CRBP, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/11/2025Q2 2025TARAProtara Therapeutics-$0.43-$0.35+$0.08-$0.35N/AN/A8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.55-$1.44+$0.11-$1.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A9.219.21DYAIDyadic International5.402.022.02OTLKOncobiologicsN/A0.670.54TARAProtara TherapeuticsN/A12.8112.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%DYAIDyadic International27.95%OTLKOncobiologics11.20%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals4.00%DYAIDyadic International29.50%OTLKOncobiologics4.80%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.26 million11.77 millionOptionableDYAIDyadic International736.19 million25.51 millionOptionableOTLKOncobiologics2044.42 million42.29 millionOptionableTARAProtara Therapeutics3038.58 million33.76 millionOptionableDYAI, TARA, CRBP, and OTLK HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Sells 244,810 Shares of Protara Therapeutics, Inc. $TARASeptember 3 at 5:25 AM | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2 at 4:05 PM | globenewswire.comVelan Capital Investment Management LP Buys 88,800 Shares of Protara Therapeutics, Inc. $TARAAugust 31, 2025 | marketbeat.comProtara Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comCantor Fitzgerald Brokers Raise Earnings Estimates for TARAAugust 22, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 20, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of TARA Q3 EarningsAugust 16, 2025 | marketbeat.comWe're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateAugust 13, 2025 | finance.yahoo.comProtara Therapeutics (NASDAQ:TARA) Announces Quarterly Earnings ResultsAugust 12, 2025 | marketbeat.comProtara Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comProtara Beats Q2 Loss EstimatesAugust 11, 2025 | aol.comAProtara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | gurufocus.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila TimesJuly 2, 2025 | manilatimes.netMProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 2, 2025 | morningstar.comMProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - NasdaqJuly 2, 2025 | nasdaq.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial CommunityJune 30, 2025 | quiverquant.comQProtara Therapeutics Announces Addition to the Russell 3000® IndexJune 30, 2025 | globenewswire.comProtara Therapeutics, Inc. (TARA) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDYAI, TARA, CRBP, and OTLK Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$9.85 +0.11 (+1.13%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$9.90 +0.05 (+0.50%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Dyadic International NASDAQ:DYAI$0.98 +0.03 (+2.89%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.97 -0.01 (-1.14%) As of 09/3/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Oncobiologics NASDAQ:OTLK$0.89 +0.02 (+2.29%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.88 -0.01 (-1.35%) As of 05:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Protara Therapeutics NASDAQ:TARA$3.23 +0.06 (+1.89%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$3.23 0.00 (0.00%) As of 09/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
